> 1995 Publications
1. Comparative
studies of prostate cancers among US, Chinese, and Japanese patients:
characterization of histopathology, tumor angiogenesis, neuroendocrine
factors and p53 protein accumulations.
Zhau HE, Zhao L, Chung LWK, Chen B, Troncoso P, Kao C, Kojima
M, Symmans F, Zheng N, Palmer JL, Moul JW, Davis R, Ye M, Xiao
L, Hall MC:
Urologic Oncology, 1:51-63, 1995.
2. Recombinant adenovirus vector expressing wild type
p53 is a potent inhibitor of prostate cancer cell proliferation.
Srivastava S, Katayose D, Tong YA, Craig CR, McLeod DG, Moul
JW, Cowan K, and Seth P:
Urology 46:843-848, 1995..
3. Increased
p53 protein does not correlate to p53 gene mutations in microdissected
human testicular germ cell tumors.
Schenkman NS, Washington L, Sesterhenn IA, Tong YA, Weghorst CM,
Buzzard GS, Srivastava S, and Moul JW:
J Urol, 154:617-621, 1995.
4. Molecular
implications of the antiandrogen withdrawal syndrome.
Moul JW, Srivastava S and McLeod DG:
Seminars in Urol., 13:157-163, 1995.
5. Proper
Staging Techniques in Testicular Cancer Patients.
Moul JW:
Techniques in Urology, 1:126-132, 1995.
6. New
medicine emerging from genes that control cancer.
Moul JW:
Contemp Ob/Gyn, 40(2): 79-87, 1995.
7. Chest
and Abdominal Staging in Testicular Cancer Patients.
Moul JW:
Med Imaging Int., 5(4):14-18, 1995.
8. Chest
and abdominal staging for testicular cancer.
Moul JW:
Contemp Urol, 7(5):57-72, 1995.
9. Neural
network analysis of quantitative histological factors to predict
pathologic stage in clinical stage I nonseminomatous testicular
cancer.
Moul JW, Snow PB, Fernandez EB, Maher PD, and Sesterhenn IA:
J Urol, 153:1674-1677, 1995.
10. Prostate-specific
antigen values at the time of prostate cancer diagnosis are higher
in African-American men.
Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S,
Mostofi FK, McLeod DG:
J Am Med Assoc., 274:1277-1281, 1995.